Family Physician Motivation and Well-Being in the Digital Era.

PURPOSE: Family physicians rapidly shifted to using virtual care during the COVID-19 pandemic, yet it is largely unknown if this change has impacted their workplace motivation. A better understanding of this matter is essential for optimizing the integration of virtual care into standard practice and for supporting family physician well-being. Using a self-determination theory lens, we examined if family physicians experienced autonomous (vs controlled) motivation toward using virtual care, how this related to their subjective well-being, and whether satisfaction (vs frustration) of their basic psychological needs at work mediated that relationship. METHODS: Using cross-sectional survey methodology, quantitative data was collected from 156 family physicians in Alberta, Canada. The questionnaire contained validated scales for measuring motivational quality, workplace need fulfillment, and subjective well-being. Descriptive, correlational, and mediation analyses were performed. RESULTS: Family physicians varied significantly in their quality of motivation towards using virtual care. Controlled motivation toward using virtual care was associated with lower well-being, and workplace need frustration fully mediated that relationship. Conversely, workplace need satisfaction, but not autonomous motivation toward using virtual care, was associated with higher well-being. CONCLUSIONS: In line with self-determination theory, findings suggest that when family physicians' motivation toward using virtual care is less self-determined, it will lead to poorer subjective well-being, because of basic psychological need frustration. Potential implications of the findings are discussed within the contexts of virtual health and primary care.

Use of liothyronine (L-T3) as an augmentation therapy for depression during pregnancy.

The thyroid hormone triiodothyronine (T3) can be used as an augmentation therapy for depression. This case involves a patient who had been initiated on liothyronine (L-T3) for this purpose and subsequently became pregnant. The exogenous T3 affected maternal thyroid hormone production, including suppression of her thyroxine (T4) levels. In pregnancy, maternal T4 is important for fetal neurodevelopment. Accordingly, use of exogenous T3 for adjunct treatment of depression in pregnant patients or those planning pregnancy requires careful laboratory monitoring of thyroid function tests. In this case, L-T3 was discontinued and the patient was eventually started on levothyroxine (L-T4) and went on to have an uneventful pregnancy.

Chronic kidney disease in type 2 diabetes: Does an abnormal urine albumin-to-creatinine ratio need to be retested?

OBJECTIVE: To determine the positive predictive value (PPV) of a single random abnormal urine albumin-to-creatinine ratio (ACR) compared with repeat test results in patients with type 2 diabetes to diagnose chronic kidney disease (CKD). DESIGN: Retrospective, longitudinal secondary data analysis using Calgary Laboratory Services data. SETTING: Calgary, Alta. PARTICIPANTS: Patients aged 21 and older with a new diagnosis of diabetes in the study period from January 2008 to December 2015 and with a first abnormal urine ACR followed by another ACR test completed within 120 days. MAIN OUTCOME MEASURES: The PPV of an abnormal urine ACR (2 to 20 mg/mmol) to diagnose CKD was calculated. A test result was considered a true positive if a subsequent positive test result (≥ 2 mg/mmol) was identified within 120 days of the first positive test result and a false positive if 2 subsequent negative test results were identified within the same time period. The relationship between the first and second urine ACR values to assess the probability of the second urine ACR being abnormal (≥ 2 mg/mmol) based on the values of the first abnormal urine ACR was also explored. RESULTS: The PPV of the first abnormal urine ACR between 2 and 20 mg/mmol to diagnose CKD was calculated at 96.80% (95% CI 95.37% to 98.21%). Additionally, there was increased predictive probability of the second urine ACR being abnormal at higher values of the first urine ACR (2 to 20 mg/mmol). The data were further analyzed to exclude test results with a new or changed prescription of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker medications around the time of the first urine ACR test to focus results on screening and not treatment response. With these exclusions, the PPV for first urine ACR between 2 and 20 mg/mmol to diagnose CKD was calculated as 96.23% (95% CI 94.13% to 98.32%). CONCLUSION: The first random abnormal urine ACR has a good PPV for the diagnosis of CKD in patients with type 2 diabetes, so multiple random urine ACR tests might not be necessary to diagnose patients with type 2 diabetes as having persistent microalbuminuria and CKD. A simpler diagnostic model for diagnosing renal disease might improve patient compliance, efficiency of testing, and implementation of health interventions. Reduced testing would also be expected to result in reduced cost from a health care expenditure perspective.